News

Pursuant to the MTA, Revive Therapeutics will obtain access to confidential information and clinical trial supply of the drug bucillamine for Revive Therapeutics’ human clinical trial of REV-002,

The COAST (Patients with Stage IV COlorectal Cancer treated with Adjuvant Regorafenib Versus Placebo after Curative Treatment of Liver Metastases in A Randomized, Double-blind, Placebo-controlled Phase-III Study) clinical

The company said that FTI, a combination of fosfomycin and tobramycin, is ready for Phase III clinical trials, having completed a Phase II trial in CF patients. FTI

In conjunction with the licensing deal, BioMotiv has established Kodosil Bio which will develop all compounds resulting from the license. BioAtla president and CEO Jay Short said the

The expanded deal into multiple therapeutic areas has been expanded owing to Jubilant’s skill sets in several therapeutic areas. The collaboration has been expanded to use Jubilant’s drug

The trial is designed to evaluate the tolerability, safety, pharmacokinetics and performance on a battery of tests in patients with symptomatic HD. Around 120 patients with Huntington’s disease

The pricing is set at $0.25 per share for 144 restricted shares coupled with a one-year warrant for $0.50 per share to comprise a complete unit offering. The

The company is seeking approval of oritavancin is for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible gram-positive bacteria, including methicillin-resistant Staphylococcus

The new patent, entitled ‘Perivascular Mesenchymal Precursor Cell Induced Blood Vessel Formation’, provides the company with exclusive commercial rights in Europe initially through to 29 March 2024, with